Advances in Pharmacological and Pharmaceutical Sciences,
Journal Year:
2024,
Volume and Issue:
2024(1)
Published: Jan. 1, 2024
High
mortality
and
disability
have
been
principally
linked
with
traumatic
brain
injury
(TBI)
this
condition
being
a
principal
issue
in
public
health.
Currently,
there
is
no
reliable
pharmaceutical
agent
to
salvage
the
damage
caused
by
TBI.
Baicalein
(BCL),
traditional
Chinese
medicine
active
ingredient,
has
preliminarily
shown
repair
activity
on
injury.
However,
BCL
poor
water
solubility
bioavailability,
which
culminates
rapid
elimination
vivo.
Herein,
we
sought
solve
above‐mentioned
challenges
that
are
associated
application
of
flavonoid
preparing
BCL‐loaded
long‐circulating
liposomes
(BLC‐Lips)
via
thin‐film
hydration
method.
Subsequently,
BLC‐Lips
were
applied
TBI
model
mice
evaluate
their
effect
repair.
The
results
showed
prepared
exhibited
smaller
sized
nanoparticles,
excellent
polydispersed
index
(PDI),
zeta
(
ζ
)‐potential
stable
property.
After
loading
into
liposomes,
estimated
physicochemical
properties
be
roughly
87.98%
(encapsulation
efficiency
[EE])
7.56%
(loading
capacity
drug).
Administration
through
oral
route
increased
aqueous
solubility,
time
for
vivo
circulation
BCL.
Moreover,
could
improve
outcomes
histological
neurological
motor
function
reduce
inflammatory
cytokines
neurotoxicity
after
Taken
together,
may
serve
as
new
approach
potentially
prolong
drug
bioavailability
treatment.
International Journal of Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
670, P. 125186 - 125186
Published: Jan. 8, 2025
The
blood-brain
barrier
(BBB)
plays
a
vital
role
in
protecting
the
central
nervous
system
(CNS)
by
preventing
entry
of
harmful
pathogens
from
bloodstream.
However,
this
also
presents
significant
obstacle
when
it
comes
to
delivering
drugs
for
treatment
neurodegenerative
diseases
and
brain
cancer.
Recent
breakthroughs
nanotechnology
have
paved
way
creation
wide
range
nanoparticles
(NPs)
that
can
serve
as
carriers
diagnosis
therapy.
Regarding
their
promising
properties,
organic
NPs
potential
be
used
effective
drug
delivery
across
BBB
based
on
recent
advancements.
These
remarkable
ability
penetrate
using
various
mechanisms.
This
review
offers
comprehensive
examination
intricate
structure
distinct
properties
BBB,
emphasizing
its
crucial
function
preserving
balance
regulating
transport
ions
molecules.
disruption
conditions
such
stroke,
Alzheimer's
disease,
Parkinson's
disease
highlights
importance
developing
creative
approaches
drugs.
Through
encapsulation
therapeutic
molecules
precise
targeting
processes
vasculature,
NP
formulations
present
hopeful
strategy
improve
BBB.
We
explore
changes
pathological
investigate
factors
affect
successful
into
brain.
In
addition,
we
most
systems
associated
with
shown
positive
results
treating
ischemic
disorders.
opens
up
new
possibilities
nanotechnology-based
therapies
cerebral
diseases.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(23), P. 12613 - 12613
Published: Nov. 24, 2024
Neurodegenerative
diseases,
such
as
Alzheimer's,
Parkinson's,
ALS,
and
Huntington's,
remain
formidable
challenges
in
medicine,
with
their
relentless
progression
limited
therapeutic
options.
These
diseases
arise
from
a
web
of
molecular
disturbances-misfolded
proteins,
chronic
neuroinflammation,
mitochondrial
dysfunction,
genetic
mutations-that
slowly
dismantle
neuronal
integrity.
Yet,
recent
scientific
breakthroughs
are
opening
new
paths
to
intervene
these
once-intractable
conditions.
This
review
synthesizes
the
latest
insights
into
underlying
dynamics
neurodegeneration,
revealing
how
intertwined
pathways
drive
course
diseases.
With
an
eye
on
most
promising
advances,
we
explore
innovative
therapies
emerging
cutting-edge
research:
nanotechnology-based
drug
delivery
systems
capable
navigating
blood-brain
barrier,
gene-editing
tools
like
CRISPR
designed
correct
harmful
variants,
stem
cell
strategies
that
not
only
replace
lost
neurons
but
foster
neuroprotective
environments.
Pharmacogenomics
is
reshaping
treatment
personalization,
enabling
tailored
align
individual
profiles,
while
diagnostics
biomarkers
ushering
era
early,
precise
disease
detection.
Furthermore,
novel
perspectives
gut-brain
axis
sparking
interest
mounting
evidence
suggests
microbiome
modulation
may
play
role
reducing
neuroinflammatory
responses
linked
neurodegenerative
progression.
Taken
together,
advances
signal
shift
toward
comprehensive,
personalized
approach
could
transform
care.
By
integrating
techniques,
this
offers
forward-looking
perspective
future
where
treatments
aim
just
manage
symptoms
fundamentally
alter
progression,
presenting
renewed
hope
for
improved
patient
outcomes.
Biomolecules,
Journal Year:
2024,
Volume and Issue:
14(8), P. 906 - 906
Published: July 25, 2024
Schizophrenia
is
a
frequently
debilitating
and
complex
mental
disorder
affecting
approximately
1%
of
the
global
population,
characterized
by
symptoms
such
as
hallucinations,
delusions,
disorganized
thoughts
behaviors,
cognitive
dysfunction,
negative
symptoms.
Traditional
treatment
has
centered
on
postsynaptic
dopamine
antagonists,
commonly
known
antipsychotic
drugs,
which
aim
to
alleviate
improve
functioning
quality
life.
Despite
availability
these
medications,
significant
challenges
remain
in
schizophrenia
therapeutics,
including
incomplete
symptom
relief,
resistance,
medication
side
effects.
This
opinion
article
explores
advancements
treatment,
emphasizing
molecular
mechanisms,
novel
drug
targets,
innovative
delivery
methods.
One
promising
approach
strategies
that
target
neural
networks
circuits
rather
than
single
neurotransmitters,
acknowledging
complexity
brain
region
interconnections
involved
schizophrenia.
Another
development
biased
agonists,
selectively
activate
specific
signaling
pathways
downstream
receptors,
offering
potential
for
more
precise
pharmacological
interventions
with
fewer
The
concept
polypharmacy,
where
targets
multiple
pathways,
exemplified
KarXT,
combining
xanomeline
trospium
address
both
psychosis
dysfunction.
represents
comprehensive
strategy
potentially
improving
outcomes
patients.
In
conclusion,
advancing
understanding
exploring
therapeutic
hold
promise
addressing
unmet
needs
aiming
effective
tailored
interventions.
Future
research
should
focus
approaches
achieve
better
clinical
functional
level
life
individuals
Molecular Neurobiology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 9, 2025
Abstract
Oxidative
stress
and
neuroinflammation
play
a
pivotal
role
in
pathomechanisms
of
brain
ischemia.
Our
research
aimed
to
formulate
nanotheranostic
system
for
delivering
carnosic
acid
as
neuroprotective
agent
with
anti-oxidative
anti-inflammatory
properties
ischemic
tissue,
mimicked
by
organotypic
hippocampal
cultures
(OHCs)
exposed
oxygen–glucose
deprivation
(OGD).
In
the
first
part
this
study,
nanocarriers
were
formulated
encapsulating
two
types
nanocores
(nanoemulsion
(AOT)
polymeric
(PCL))
containing
CA
into
multilayer
shells
using
sequential
adsorption
charged
nanoobjects
method.
The
newly
designed
nanoparticles
possessed
favorable
physicochemical
characteristics
reflected
zeta
potential
other
parameters.
Next,
we
demonstrated
that
gadolinium-containing
not
toxic
OHCs
did
affect
detrimental
effects
OGD
on
viability
cells.
Importantly,
they
readily
crossed
artificial
blood–brain
barrier
based
human
cerebral
microvascular
endothelial
(hCMEC/D3)
cell
line.
Furthermore,
PCL-Gd
acid–loaded
displayed
potential,
expressed
decreased
OGD-induced
HIF-1α
IL-1β
levels.
Results
molecular
study
revealed
complex
mechanism
nanoformulation
ischemia-related
OHCs,
including
protein
A20
stimulation
moderate
attenuation
NFκB
signaling
pathway.
Summing
up,
points
acceptable
biocompatibility
CA-containing
theranostic
emphasizes
their
interaction
inflammatory
processes
commonly
associated
brain.
Graphical
Cell Proliferation,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 11, 2025
ABSTRACT
In
spite
of
great
advances
in
modern
medicine,
there
are
a
few
effective
strategies
for
the
treatment
neurodegenerative
diseases
characterised
by
neuron
loss
or
degeneration.
This
results
from
complex
pathogenesis
and
limited
drug
uptake
brain
due
to
presence
blood‐brain
barrier.
Nanoparticle‐based
delivery
systems
expected
improve
utilisation.
Polymeric
nanoparticles
represent
promising
carriers
their
unique
advantages
such
as
good
biodegradability
biocompatibility,
flexibility
surface
modification
nontoxicity.
addition,
genetic
drugs
may
stop
progression
at
level
even
avoid
irreversible
damage
central
nervous
system.
this
review,
an
overview
studies
on
polymer‐based
system
typical
diseases,
especially
Alzheimer's
Parkinson's
is
described.
Meanwhile,
applications
gene
these
disorders
discussed.
And
challenges
future
perspectives
development
polymeric
concluded.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: March 27, 2025
Abstract
Glioma
remains
a
significant
global
health
challenge,
and
is
characterized
by
persistently
high
mortality
rate.
Chemotherapy
common
treatment
for
glioma,
but
many
anticancer
drugs
exhibit
poor
permeability
across
the
blood–brain
barrier
(BBB)
fail
to
reach
tumor
tissues
adequately,
while
also
exerting
toxic
effects
on
normal
cells.
To
address
these
issues,
this
study
investigated
use
of
niosomes
(Nio),
which
are
biocompatible,
biodegradable,
non-immunogenic,
encapsulate
curcumin
(Cur)
enhance
its
delivery
glioma
tissues.
Niosomes
were
prepared
using
non-ionic
surfactant
sorbitan
monostearate
(Span
60)
cholesterol
as
carrier
materials,
subsequently
modified
with
transferrin
(TF)
facilitate
receptor-mediated
transport
BBB.
The
resulting
TF-modified
(TF-Cur-Nio)
demonstrated
enhanced
targeting
brain
tumors,
improved
anti-glioma
efficacy,
favorable
in
vivo
safety.
These
findings
suggest
that
TF-Cur-Nio
system
has
potential
advancing
overcoming
limitations
conventional
chemotherapy
improving
drug
brain.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
17(2)
Published: March 1, 2025
ABSTRACT
The
field
of
nanomedicine
offers
revolutionary
potential
to
reshape
the
discovery
and
development
therapeutics
for
diverse
human
diseases.
However,
its
application
has
been
limited
in
improving
Substance
Use
Disorders
(SUDs),
which
represent
a
profound
public
health
crisis,
including
major
types
such
as
opioid,
alcohol,
stimulant,
cannabis
use
disorders.
Pharmacotherapy,
cornerstone
SUD
management,
reduced
morbidity,
mortality,
societal
impact
addiction,
though
efficacy
ranged
from
none
moderate.
Thus,
there
is
unmet
need
transform
pharmacotherapy
curb
epidemic
addiction.
This
article
explores
roles
nanomedicine‐inspired
precision‐targeted
drug
delivery,
sustained
release,
combination
therapies
increase
therapeutic
minimize
side
effects.
Additionally,
it
discusses
innovative
mechanisms
that
align
with
neurobiological
complexities
addiction
synergistic
approaches
integrate
behavioral
interventions,
device‐based
therapies,
emerging
modalities
immunotherapy
neurostimulation.
Despite
these
advancements,
barriers
treatment
accessibility,
adherence
challenges,
inequitable
resource
distribution
persist,
particularly
underserved
populations.
By
harnessing
transformative
capabilities
integrating
into
holistic,
equitable,
personalized
care
frameworks,
this
review
highlights
path
forward
revolutionize
landscape.
underscores
continued
nano‐SUD
research
strategies
alleviate
substantial
burden
on
individuals,
families,
society.
